268 related articles for article (PubMed ID: 31079801)
1. Role of Surgery in Combination with Immunotherapy.
Klemen ND; Shindorf ML; Sherry RM
Surg Oncol Clin N Am; 2019 Jul; 28(3):481-487. PubMed ID: 31079801
[TBL] [Abstract][Full Text] [Related]
2. Role of Surgery for Metastatic Melanoma.
Enomoto LM; Levine EA; Shen P; Votanopoulos KI
Surg Clin North Am; 2020 Feb; 100(1):127-139. PubMed ID: 31753107
[TBL] [Abstract][Full Text] [Related]
3. Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response.
Gingrich AA; Kirane AR
Surg Oncol Clin N Am; 2020 Jul; 29(3):467-483. PubMed ID: 32482321
[TBL] [Abstract][Full Text] [Related]
4. Role of Surgery in Stage IV Melanoma.
O'Neill CH; McMasters KM; Egger ME
Surg Oncol Clin N Am; 2020 Jul; 29(3):485-495. PubMed ID: 32482322
[TBL] [Abstract][Full Text] [Related]
5. Finding the right combination for neoadjuvant therapy in high-risk, stage III melanoma.
Amaria R; Caffrey M
Am J Manag Care; 2019 Feb; 25(2 Spec No.):SP43-SP44. PubMed ID: 30776211
[No Abstract] [Full Text] [Related]
6. Use of immunotherapy and surgery for stage IV melanoma.
Molina G; Kasumova GG; Qadan M; Boland GM
Cancer; 2020 Jun; 126(11):2614-2624. PubMed ID: 32157676
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapy following metastasectomy for renal cell carcinoma: Using insights from other clinical settings to address unanswered questions.
Appleman LJ; Maranchie JK
Urol Oncol; 2018 Jan; 36(1):17-22. PubMed ID: 28736252
[TBL] [Abstract][Full Text] [Related]
8. Surgical Considerations and Systemic Therapy of Melanoma.
Gamboa AC; Lowe M; Yushak ML; Delman KA
Surg Clin North Am; 2020 Feb; 100(1):141-159. PubMed ID: 31753109
[TBL] [Abstract][Full Text] [Related]
9. The impact of effective systemic therapies on surgery for stage IV melanoma.
Smith MJF; Smith HG; Joshi K; Gore M; Strauss DC; Hayes AJ; Larkin J
Eur J Cancer; 2018 Nov; 103():24-31. PubMed ID: 30196107
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
Ralli M; Botticelli A; Visconti IC; Angeletti D; Fiore M; Marchetti P; Lambiase A; de Vincentiis M; Greco A
J Immunol Res; 2020; 2020():9235638. PubMed ID: 32671117
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy for high-risk bulky regional melanoma.
Tarhini AA; Pahuja S; Kirkwood JM
J Surg Oncol; 2011 Sep; 104(4):386-90. PubMed ID: 21858833
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for melanoma.
Cuevas LM; Daud AI
Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for advanced melanoma: fulfilling the promise.
Gogas H; Polyzos A; Kirkwood J
Cancer Treat Rev; 2013 Dec; 39(8):879-85. PubMed ID: 23725878
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Treatments for Advanced Resectable Melanoma.
Liu JY; Lowe M
J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
[TBL] [Abstract][Full Text] [Related]
15. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
McKean MA; Amaria RN
Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop.
Mueller KL; Theoret MR; Lemery SJ; Amiri-Kordestani L; Ariyan CE; Atkins MB; Berry DA; Blank CU; DeMichele AM; Forde PM; Ibrahim N; Keegan P; Mitchell TC; Moss RA; Robert C; Sridhara R; Taube JM; Tetzlaff MT; Wargo JA; Flaherty KT; Kaplan MJ; Topalian SL; Ward AF; Hurlbert MS
Clin Cancer Res; 2021 Jan; 27(2):394-401. PubMed ID: 33188142
[TBL] [Abstract][Full Text] [Related]
17. Principles of Immunotherapy in Melanoma.
Onitilo AA; Wittig JA
Surg Clin North Am; 2020 Feb; 100(1):161-173. PubMed ID: 31753110
[TBL] [Abstract][Full Text] [Related]
18. A role of immunotherapy in metastatic malignant melanoma.
Allen T; Gundrajakuppam L
Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):182-8. PubMed ID: 22697295
[TBL] [Abstract][Full Text] [Related]
19. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
Lau PK; Ascierto PA; McArthur G
Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
[TBL] [Abstract][Full Text] [Related]
20. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
